Rating Change
Citizens reiterated its Market Outperform rating on Allogene Therapeutics, Inc. (NASDAQ:ALLO) on August 17, 2026.
reiterateNASDAQ:ALLO
Citizens Reiterates Market Outperform Rating on Allogene Therapeutics, Inc. (ALLO)
Citizens reiterated its Market Outperform rating on Allogene Therapeutics, Inc. (NASDAQ:ALLO) on August 17, 2026.
At publication ·
What changed
Allogene Therapeutics, Inc. (NASDAQ:ALLO) · reiterate
- Firm
- Citizens
- Rating
- Market Outperform to Market Outperform
- Price at event
- $2.08
- Market capitalization
- $624.7M
At a glance
Key takeaways
- Citizens reiterated a Market Outperform rating on Allogene Therapeutics (ALLO) on August 17, 2026, with the stock trading at $2.08 and a market capitalization of $624.7 million.
Market Context
Allogene Therapeutics, Inc. operates in the Healthcare sector. The stock currently trades at $2.08 with a market capitalization of $624.7M. The stock has gained 93.4% over the past 52 weeks.
Analyst coverage from Citizens provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Allogene Therapeutics, Inc.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Allogene Therapeutics, Inc.
Among the 10 most recent ratings: 7 Buy, 3 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Aug 17, 2026 | Citizens | Market Outperform | N/A |
| Apr 16, 2026 | HC Wainwright & Co. | Buy | N/A |
| Apr 16, 2026 | JP Morgan | Neutral | N/A |
| Apr 15, 2026 | Jefferies | Buy | N/A |
| Apr 14, 2026 | Bernstein | Market Perform | N/A |
Related Tools: Analyst Ratings Dashboard | View ALLO Stock Page
Frequently Asked Questions
What does the Market Outperform rating mean for ALLO?
A rating of Market Outperform from Citizens reflects the analyst's outlook on Allogene Therapeutics, Inc. (NASDAQ:ALLO). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the ALLO forecast page.